Ignite Creation Date:
2025-12-24 @ 9:47 PM
Ignite Modification Date:
2025-12-25 @ 7:26 PM
Study NCT ID:
NCT00778232
Status:
COMPLETED
Last Update Posted:
2008-10-23
First Post:
2008-10-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077206', 'term': 'Gabapentin'}], 'ancestors': [{'id': 'D000588', 'term': 'Amines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D005680', 'term': 'gamma-Aminobutyric Acid'}, {'id': 'D000613', 'term': 'Aminobutyrates'}, {'id': 'D002087', 'term': 'Butyrates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D003509', 'term': 'Cyclohexanecarboxylic Acids'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D003510', 'term': 'Cyclohexanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 22}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2002-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2008-10', 'completionDateStruct': {'date': '2002-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2008-10-22', 'studyFirstSubmitDate': '2008-10-22', 'studyFirstSubmitQcDate': '2008-10-22', 'lastUpdatePostDateStruct': {'date': '2008-10-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-10-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2002-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Bioequivalence'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Bioequivalence Gabapentin tablets 800 mg fed conditions'], 'conditions': ['Healthy']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://clinicalstudies.ranbaxy.com', 'label': 'Related Info'}, {'url': 'http://dailymed.nlm.nih.gov/dailymed/about.cfm', 'label': 'Related Info'}, {'url': 'http://www.fda.gov/opacom/7alerts.html', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral dose (1x800 mg tablet) in healthy adult volunteers under non-fasting conditions.', 'detailedDescription': 'A single oral dose of the test or the reference product was administered to 22 healthy adult human volunteers on two separate occasions under non-fasting conditions with at least a 7 day washout between the doses. Food and the fluid intake were controlled during each confinement period.\n\nTwenty two (22) healthy adult human volunteers (12 males and 10 females) were enrolled in the study. All twenty two (22) subjects successfully completed the clinical portion of the study'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. All volunteers selected for the study will be healthy men or women 18 years of age or older at the time of dosing\n2. The weight will no exceed ± 20% for the height and body frame as per desirable weight for adults - 1983 Metropolitan height and weight table\n3. If female and Of Child bearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator (s), such as condoms , foams, jellies, diaphragm, intrauterine devices (IUD), or abstinence; or Is postmenopausal for at least 1 year; or Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)\n\nExclusion Criteria:\n\n1. volunteers with a recent history of drug or alcohol addiction or abuse\n2. Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system (s) or psychiatric disease (as determined by the clinical investigators)\n3. Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant\n4. Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen\n5. Volunteers demonstrating a positive drug abuse screen when screened for this study\n6. Female volunteers demonstrating a positive pregnancy screen\n7. Female volunteers who are currently breast feeding\n8. Volunteers with a history of allergic response (s) to Gabapentin or related drugs\n9. Volunteers with a history of clinically significant allergies including drug allergies\n10. Volunteers with a clinically significant illness during the 4 weeks prior to period I dosing (as determined by the clinical investigators)\n11. Volunteers who are currently using tobacco products\n12. Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to period I dosing\n13. Volunteers who report donating greater than 150 mL of blood within 30 days prior to period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study\n14. Volunteers who have donated plasma (eg. Plasmapheresis) within 14 days prior to period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study\n15. Volunteers who report receiving any investigational drug within 30 days prior to period I dosing\n16. Volunteers who report taking any systemic prescription medication in the 14 days prior to period I dosing.'}, 'identificationModule': {'nctId': 'NCT00778232', 'briefTitle': 'Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions', 'organization': {'class': 'INDUSTRY', 'fullName': 'Ranbaxy Inc.'}, 'officialTitle': 'A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Non-Fasting Conditions', 'orgStudyIdInfo': {'id': 'R01-826'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'description': 'Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited', 'interventionNames': ['Drug: Gabapentin tablets 800 mg']}, {'type': 'ACTIVE_COMPARATOR', 'label': '2', 'description': 'Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd', 'interventionNames': ['Drug: Gabapentin tablets 800 mg']}], 'interventions': [{'name': 'Gabapentin tablets 800 mg', 'type': 'DRUG', 'armGroupLabels': ['1', '2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '58104', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'PRACS Institute Ltd.', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ranbaxy Laboratories Limited', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Dr. Tausif Monif', 'oldOrganization': 'Ranbaxy Research Labs'}}}}